Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses
- PMID: 10503802
- DOI: 10.1016/s0197-2456(99)00021-5
Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses
Abstract
An important but difficult task in the design of a clinical trial to compare time to failure between two treatment groups is determination of the number of patients required to achieve a specified power of the test. Because patients typically enter the trial serially and are followed until they fail or withdraw from the study or until the study is terminated, the power of the test depends on the accrual pattern, the noncompliance rate, and the withdrawal rate in addition to the actual survival distributions of the two groups. Incorporating interim analyses and the possibility of early stopping into the trial increases its complexity, and although normal approximations have been developed for computing the significance level of the test when the log-rank or other rank statistics are used, there are no reliable analytic approximations for evaluating the power of the test. This article presents methods, based on Monte Carlo simulations and recent advances in group sequential testing with time-to-event responses, to choose appropriate test statistics, compute power and sample size at specified alternatives, check the adequacy of commonly used normal approximations of the type I error probability, and assess the performance of different interim analysis strategies. It also presents two computer programs implementing these methods.
Comment in
-
A simulation approach to determining sample size and power for group sequential trials.Control Clin Trials. 2002 Apr;23(2):182-3. doi: 10.1016/s0197-2456(01)00178-7. Control Clin Trials. 2002. PMID: 11943445 No abstract available.
Similar articles
-
Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.Biometrics. 1998 Jun;54(2):682-95. Biometrics. 1998. PMID: 9629648
-
Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.Pharm Stat. 2020 Sep;19(5):583-601. doi: 10.1002/pst.2014. Epub 2020 Apr 5. Pharm Stat. 2020. PMID: 32248662
-
Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.Biom J. 2008 Apr;50(2):224-36. doi: 10.1002/bimj.200710388. Biom J. 2008. PMID: 18264992
-
Monitoring clinical trials with a conditional probability stopping rule.Stat Med. 1992 Mar;11(5):659-72. doi: 10.1002/sim.4780110510. Stat Med. 1992. PMID: 1594808
-
Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.Contemp Clin Trials. 2012 Jan;33(1):138-42. doi: 10.1016/j.cct.2011.09.003. Epub 2011 Sep 29. Contemp Clin Trials. 2012. PMID: 21983624 Review.
Cited by
-
Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India--the HIVIND study protocol.BMC Med Res Methodol. 2010 Mar 26;10:25. doi: 10.1186/1471-2288-10-25. BMC Med Res Methodol. 2010. PMID: 20346136 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources